Biotechnology company developing universal AAV immuno-gene therapies for cancer
Biotechnology company developing universal AAV immuno-gene therapies for cancer. Its platform uses adeno-associated virus vectors to deliver immune-modulating cargo, such as cytokines, into tumors to stimulate anti-tumor immunity. Lead candidate SRN-101 is being evaluated in a Phase 1 study for recurrent high-grade glioma.